Bioscience

PANEL: Life sciences will see radically different futureRestricted Content

May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.

Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.

The following is an unedited transcript of the discussion.

More

IU medical school's push to launch startups bears fruitRestricted Content

April 13, 2013
J.K. Wall
The Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity the school has never seen before.
More

Health care startups hungry for fundsRestricted Content

February 2, 2013
J.K. Wall
Frustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create a dedicated funding stream that could total $30 million a year.
More

Zimmer's earnings slip, but beat expectations

January 31, 2013
 IBJ Staff
Fourth-quarter profit fell 2 percent at Zimmer Holdings Inc. due to large accounting charges, but still beat the estimates of Wall Street analysts.
More

BioCrossroads seed fund makes first investments

January 10, 2013
Local startups Esanex Inc. and Algaeon Inc. have received $500,000 and $250,000, respectively, from Indiana Seed Fund II, BioCrossroads' second fund to help fledgling life sciences companies.
More

Nico raises $6.5 million more from existing investors

December 4, 2012
J.K. Wall
Indianapolis-based Nico Corp. wants to use its new round of capital to develop brain surgery products to address diseases that were often considered inoperable, such as metastatic brain cancer and intracerebral hemorrhages.
More

BioCrossroads has stoked state's life sciences industry, but challenges remainRestricted Content

February 11, 2012
J.K. Wall
In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.
More

Dow Agro posts record fourth quarter profit

February 2, 2012
 IBJ Staff and Associated Press
The Indianapolis-based unit of Dow Chemical Co. saw earnings grow to $142 million, a fourth-quarter record and double the $72 million reported for the 2010 period.
More

BioCrossroads seeds upstart medical device maker

October 20, 2011
Chris O'Malley
BioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company chaired by a former Eli Lilly and Co. executive developing an absorbable stent.
More

Ex-Dow Agro scientist makes plea in trade-secret case

September 15, 2011
Associated Press
A former Indiana scientist has agreed to plead guilty to charges of illegally sending trade secrets worth $300 million to China and Germany.
More

Medical implant maker plans move from northern Indiana

August 4, 2011
Associated Press
Rochester Medical Implants plans to move operations from Rochester to Noblesville in October. The company has 28 employees.
More

More life sciences firms opt to launch products in EuropeRestricted Content

July 30, 2011
Maria LaMagna
The U.S. Food and Drug Administration's growing reputation for unpredictability is spurring some Indianapolis companies to join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations occurring in their backyards.
More

Indiana life sciences leaders look toward the futureRestricted Content

July 30, 2011
Chris O'Malley
Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue's Discovery Park.
More

Tech district could boost Indianapolis' convention businessRestricted Content

July 23, 2011
Scott Olson
The Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
More

Lilly plans more investment in two-in-one drugs

June 28, 2011
J.K. Wall
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
More

Anson Group CEO thrives on helping clients work with FDARestricted Content

June 11, 2011
Ann Finch
Colleen Hittle became CEO and sole owner of the Indianapolis-based pharmaceutical and medical device consulting firm in April.
More

City to roll out plan for 16th Street tech corridor

June 10, 2011
Francesca Jarosz
The city of Indianapolis plans to announce a major initiative to turn a stretch of 16th Street northwest of downtown into a hub for biotechnology and other high-tech companies.
More

Life sciences logistics firm opens new tissue storage facility

May 27, 2011
J.K. Wall
BioStorage Technologies' $4.6 million facility, located near the Indianapolis International Airport, will be used to prepare, store and transport tissue and blood samples.
More

Tax breaks approved for bioanalytical lab operator

April 7, 2011
The Metropolitan Development Commission on Wednesday preliminarily approved Advion BioServices Inc.'s request for a tax abatement to build a laboratory at Purdue Research Park in Indianapolis.
More

Bioanalytical researcher seeking abatement for new lab

April 5, 2011
Scott Olson
Advion, a provider of bioanalytical research and a subsidiary of Ithaca, N.Y.-based Advion BioSciences Inc., is expected to open the 22,000-square-foot lab in mid-May with 49 employees, according to the company's application.
More

Scientists question claims in biotech letter

April 1, 2011
Associated Press
The widespread Internet posting of a letter by a retired Purdue University researcher who says he has linked genetically modified corn and soybeans to crop diseases and to abortions and infertility in livestock has raised concern among scientists that the public will believe his unsupported claim is true.
More

Marcadia Biotech principals ponder next course

March 22, 2011
Chris O'Malley
Marcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
More

Research jobs could flow from Purdue quadRestricted Content

March 19, 2011
Marc D. Allan
Purdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers who might well have left the state for either coast.
More

Molecules are moneymakers for software firm Indigo BioSystemsRestricted Content

January 29, 2011
Chris O'Malley
Eli Lilly and Co. spin-off has landed new private investment and may double its work force this year.
More

Aprimo sale may usher in 'new wave' of tech dealsRestricted Content

January 8, 2011
Chris O'Malley
Observers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not only among IT firms, but also among biotech companies here.
More
Page  1 2 3 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT